Changes in Beneficial Ownership · 4
Nurix Therapeutics, Inc.
NRIXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1792008695.xml
Filing details
- Report period
- 2026-10-14
- Issuer
- Nurix Therapeutics, Inc.
- Issuer CIK
- 0001549595
- Trading symbol
- NRIX
Reporting owner 1
- Name
- GREGORY JULIA P
- Reporting owner CIK
- 0001226675
- Relationship
- Director
- Address
- C/O NURIX THERAPEUTICS, INC., 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-14 | M · Form 4 | 22,583 | A | 1.86 | 33,333 | D |
| Common Stock | 2026-10-14 | S · Form 4 | 22,583 | D | 23.4038[F1] | 10,750 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy) | 1.86 | 2026-10-14 | M · Form 4 | 22,583 | D | 0 | [F2] | 2029-12-22 | Common Stock | 22,583 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Represents the weighted average sale price. The lowest price at which shares were sold was $23.34 and the highest price at which shares were sold was $23.62. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.↩ 1
- F2
- The stock option vested as to 1/48 of the total shares monthly beginning September 12, 2019 until the option was fully vested on August 12, 2023.↩ 1
Signature 1
- Signed
- /s/ Daniel Burbach, as Attorney-in-Fact for Julia P. Gregory
- Date
- 2026-10-14
Company context
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6, SAR448272/NX-3911, in collaboration with Sanofi, a clinical stage degrader of IRAK4, GS6791, in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix is headquartered in Brisbane, California. For additional information visit http://www.nurixtx.com.